戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 standard of care for patients with end-stage intestinal failure.
2 the intestine began to emerge as therapy for intestinal failure.
3  for short bowel syndrome and other types of intestinal failure.
4 onable option for patients with irreversible intestinal failure.
5 tion (TPN) for the treatment of irreversible intestinal failure.
6 tion and after a mean period of 5.3 years of intestinal failure.
7 now available for patients with irreversible intestinal failure.
8  intestinal transplantation as treatment for intestinal failure.
9 ptimize nutrient absorption in patients with intestinal failure.
10 ation (IT) is the final treatment option for intestinal failure.
11 (PNAC) complicates the care of patients with intestinal failure.
12 atients with IBD facing acute and/or chronic intestinal failure.
13 ients with short bowel syndrome with chronic intestinal failure.
14 support (PS) needs in patients with SBS with intestinal failure.
15 es during IBD remission, active disease, and intestinal failure.
16  for humanised grafts to treat patients with intestinal failure.
17 ity and mortality from PNALD in infants with intestinal failure.
18 of progressive liver disease in infants with intestinal failure.
19 ral nutrition (PN) is the main treatment for intestinal failure.
20 harm in the form of CCABSIs in children with intestinal failure.
21 increased medical and surgical treatment for intestinal failure.
22 ent of irreversible, permanent, and subtotal intestinal failure.
23 rition (HPN) dependence in SBS patients with intestinal failure.
24 ing procedure for patients with irreversible intestinal failure.
25  potentially life-saving treatment of severe intestinal failure.
26 n is a successful treatment for irreversible intestinal failure.
27 ues in adults and children with PN dependent intestinal failure.
28 lts and children with irreversible liver and intestinal failure.
29 le strategy in the treatment of irreversible intestinal failure.
30 periencing life-threatening complications of intestinal failure.
31 costs of patients with uncomplicated chronic intestinal failure, 28 adults, stable HPN patients were
32 e of transplantable tissue for patients with intestinal failure, a condition resulting from extensive
33 ollected data from 85 patients with SBS with intestinal failure, according to the European Society fo
34 nfections as well as at an increased risk of intestinal failure after extensive intestinal resection.
35 ng-term total parenteral nutrition (TPN) for intestinal failure and 15% to 40% of adults on home pare
36 f correctly indicated, is a clinical sign of intestinal failure and a surrogate marker for markedly i
37 ifesaving for selected patients with chronic intestinal failure and can be done with minimal risk to
38 be a life-saving procedure for patients with intestinal failure and complex abdominal pathology.
39 the treatment for patients with irreversible intestinal failure and complications of parenteral nutri
40  we show that the CTE-associated early-onset intestinal failure and lethality of Spint2-deficient mic
41 e-saving therapy available for patients with intestinal failure and life-threatening complications of
42 f cleavage-resistant EpCAM failed to prevent intestinal failure and postnatal lethality in Spint2-def
43       Short bowel syndrome (SBS) can lead to intestinal failure and require total or supplemental par
44  from patient records, the Dutch Registry of Intestinal Failure and Transplantation, the Intestinal T
45 valuated after a mean period of 5.1 years of intestinal failure and were similar to the transplant re
46                                Children with intestinal failure are at high risk for developing centr
47 arenteral nutrition (HPN) therapy in chronic intestinal failure are lacking.
48 changes may contribute to the development of intestinal failure associated liver disease (IFALD), a m
49 e protease inhibitor HAI-2, develop CTE-like intestinal failure associated with a progressive loss of
50 m infections (CRBSIs) (1.7/1000 d of PN) and intestinal failure-associated liver disease (IFALD) (51
51                               Development of intestinal failure-associated liver disease (IFALD) is a
52  been linked with serum biochemical signs of intestinal failure-associated liver disease (IFALD), whe
53 term parenteral nutrition (PN) often develop intestinal failure-associated liver disease (IFALD).
54 herapy is a safe and effective treatment for intestinal failure-associated liver disease (IFALD).
55 or to OGD for detecting GOV in children with intestinal failure-associated liver disease and results
56                                              Intestinal failure-associated liver disease develops in
57            However, the role of autophagy in intestinal failure-associated liver disease has not prev
58  for a variety of indications, most commonly intestinal failure-associated liver disease or porto-mes
59  transplantation in the event of progressive intestinal failure-associated liver disease, progressive
60 inal failure, unless complicated by advanced intestinal failure-associated liver disease, when liver-
61  or combined with glutamine in patients with intestinal failure because of short-bowel syndrome remai
62 ompare adverse outcomes (fistulation, death, intestinal failure, bleeding requiring intervention) and
63 tation (ITx) is the definitive treatment for intestinal failure but has the highest rejection rate am
64 e onset of liver disease in children >2 with intestinal failure but is not advantageous in patients <
65                   Patients with irreversible intestinal failure can then be referred for early small
66 d parenteral nutrition (PN) in patients with intestinal failure carries the risk for developing PN-as
67 aregivers and a designated multidisciplinary intestinal failure center, to enhance the prospects for
68 vers, working with specialists at designated intestinal failure centers, should develop a structured
69                        Patients with chronic intestinal failure (CIF) often develop cholestatic liver
70 rt (PS) is the standard treatment of chronic intestinal failure (CIF) with short bowel syndrome (SBS)
71 ation of this group is to establish national intestinal failure databases that can support multicente
72    Advancement in treatment of children with intestinal failure did not lead to change in generally a
73  intestinal transplantation in patients with intestinal failure expected to require parenteral nutrit
74 dren with neonatal short bowel syndrome with intestinal failure experienced long initial hospital sta
75 an be life-saving for patients with advanced intestinal failure experiencing complications of parente
76                                              Intestinal failure, following extensive anatomical or fu
77                Because a formal diagnosis of intestinal failure has not always been the key to initia
78   At baseline, children (n = 46) with severe intestinal failure highly dependent on parenteral nutrit
79 mated chyme reinfusion (CR) in patients with intestinal failure (IF) and a temporary double enterosto
80 le adult patients with short bowel syndrome, intestinal failure (IF) and dependence on parenteral sup
81 al surgery, Crohn disease (CD) may result in intestinal failure (IF) and dependency on home parentera
82                                Children with intestinal failure (IF) depend on parenteral nutrition (
83                                              Intestinal failure (IF) is a broad term encompassing var
84                          The primary goal in intestinal failure (IF) is adaptation and enteral autono
85                                              Intestinal failure (IF) is associated with significant m
86                                              Intestinal failure (IF) occurs when intestinal surface a
87  evaluate the long-term effects of pediatric intestinal failure (IF) on liver histology.
88                                Children with intestinal failure (IF) receiving long-term parenteral n
89                        Children with chronic intestinal failure (IF) treated with long-term parentera
90                             In patients with intestinal failure (IF), who are receiving home parenter
91 ving procedure for patients with complicated intestinal failure (IF).
92 s, micronutrients, and water, SBS results in intestinal failure (IF).
93 are the 2 treatment options for irreversible intestinal failure (IF).
94 d histologic liver injury in pediatric-onset intestinal failure (IF).
95 and science of the multidisciplinary care of intestinal failure in children.
96 antation has become a standard treatment for intestinal failure in patients with life-threatening com
97                 Yet the mechanism underlying intestinal failure in UNC45A deficiency remains unclear.
98 reatment options available for patients with intestinal failure including the cost of the therapy and
99    Since 2001, advances in the management of intestinal failure including transplantation and patient
100 atients with short bowel syndrome (SBS) with intestinal failure, increasing intestinal wet weight abs
101  Management strategies for the prevention of intestinal failure-induced liver disease include early e
102 ated ASMKO mice, which are unable to develop intestinal failure injury.
103               In selected cases, surgery for intestinal failure is an option with resection or bypass
104                       Septic acute liver and intestinal failure is associated with a high mortality.
105     Loss of vascular access in patients with intestinal failure is considered an indication for intes
106           Neonatal short bowel syndrome with intestinal failure is rare, and observational studies ar
107                            The main cause of intestinal failure is short bowel syndrome (SBS).
108 or infants and children with food allergies, intestinal failure, kidney disease, and metabolic disord
109 focus on the importance of multidisciplinary intestinal failure management.
110 model of survival termed Model for End-Stage Intestinal Failure (MESIF) (C-statistic 0.78).
111                            An association of intestinal failure, mutations in the NOD2 gene and tuber
112 peutic option for patients with irreversible intestinal failure or short bowel syndrome.
113 ue to improve, its role in the management of intestinal failure patients becomes clearer.
114                                         Some intestinal failure patients do well with long-term total
115  goal of improving outcomes in all long-term intestinal failure patients including those requiring in
116 transplantation; (3) National registries for intestinal failure patients should be established and or
117             (1) Primary care givers managing intestinal failure patients should establish a link with
118  transplants should be considered earlier in intestinal failure patients that develop liver injury, t
119 plantation and its role in the management of intestinal failure patients.
120 whole organ-scale technology needed to treat intestinal failure patients.There is a need for humanise
121 he point at which to refer the patient to an intestinal failure program offering autologous bowel rec
122 ure patients should establish a link with an intestinal failure programs early and collaboration with
123 ailure programs early and collaboration with intestinal failure programs should be initiated for pati
124 e than 50% 3 months after initiating PN; (2) intestinal failure programs should include both intestin
125                    Twenty-four children with intestinal failure received the ethanol lock prophylaxis
126 compared quality of life among patients with intestinal failure receiving home parenteral nutrition (
127                  The most common etiology of intestinal failure remains short-gut syndrome, which enc
128                           Many patients with intestinal failure require intestinal transplantation (I
129 d children who were 18 years or younger with intestinal failure requiring a central venous catheter.
130 ene are a significant risk factor to acquire intestinal failure requiring home parenteral nutrition.
131 blind, phase 3 trial, patients with SBS with intestinal failure requiring PS >=3 d/wk were randomized
132 aglutide treatment in patients with SBS with intestinal failure resulted in clinically relevant reduc
133 bleeding (RR = 0.74, 95% CI: 0.45-1.23), and intestinal failure (RR = 1.00, 95% CI: 0.64-1.57) were n
134                    Short bowel syndrome with intestinal failure (SBS-IF) is a rare but devastating me
135 m in patients with short-bowel syndrome with intestinal failure (SBS-IF) to gain insight into its mec
136 n in patients with short bowel syndrome with intestinal failure (SBS-IF).
137               We report of two patients with intestinal failure secondary to mesenteric ischemia.
138                  All patients with permanent intestinal failure should be managed by dedicated multid
139 nt-specific jejunal grafts for children with intestinal failure, ultimately aiding in the restoration
140  is an established treatment of irreversible intestinal failure, unless complicated by advanced intes
141 ldren with neonatal short bowel syndrome and intestinal failure was conducted between 2004 and 2020,
142 al and surgical management of the child with intestinal failure was presented with a focus on the imp
143 dren with neonatal short bowel syndrome with intestinal failure were identified (997 female [44%]; 41
144 ansplantation is now an accepted therapy for intestinal failure when parenteral nutrition therapy can
145 thrombosis, even in the absence of liver and intestinal failure, when other treatment options for var
146 ed complications (P = 0.02).In patients with intestinal failure who are life dependent on HPS, the ta
147                                 Infants with intestinal failure who are parenteral nutrition (PN)-dep
148                             In patients with intestinal failure who are receiving home parenteral sup
149  catheter related infection in patients with intestinal failure who carry mutations in their NOD2 gen
150 s the definitive treatment for patients with intestinal failure who experience severe complications o
151 is the treatment of choice for patients with intestinal failure who have developed life-threatening c
152                                Patients with intestinal failure who receive long-term parenteral nutr
153 s an important complication in patients with intestinal failure with reduced LRH-1 expression.

 
Page Top